Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
trillsg, thanks. Good stuff. It's all about the data... Good to see wastewater-based surveillance specifically being called out. Even last sentence of document is a good one, 'There is no time to waste.'
So how will Fermoy fit in?
"Globalisation, climate change, natural and man-made disasters, biodiversity loss, habitat
encroachment as well as armed conflicts and terrorism drive the emergence and escalation of
health emergencies, which can emerge anywhere on the globe and rapidly spread across
continents. The timely availability of effective countermeasures depends on high quality data
sourcing and the evaluation of potential threats, their impacts, and the identification of
innovative solutions. Europe must be ahead of the curve, having relevant structures in place to
identify and react to the next health crisis as early and effectively as possible."
Key actions:
Threat detection: Establish state of the art, real-time data and intelligence on threats, relevant countermeasures, and enabling technologies, through a full partnership with Member State expertise and enhanced collaboration with industry, international actors and institutions, as well as with EU agencies.
Threat modelling: Strengthen real-time analytics and develop accurate models to forecast
the course of an outbreak.
Epidemic surveillance: Extend support programmes set up under HERA Incubator to
strengthen the detection and identification of variants in the EU
T.Rat, some weekend reading for you, sadly I'm working it,
https://www.modernwater.com/2021/03/23/deepverge-aligned-with-eu-covid-wastewater-surveillance-approach/
The Recommendation is part of a set of COVID-19 measures adopted by the Commission as announced in the European preparedness plan entitled the ‘HERA Incubator’, which builds on an EU Umbrella Initiative of the Commission collecting the knowledge and experience in Member States regarding the surveillance of COVID-19 and its variants in wastewaters.
Released yesterday:
https://ec.europa.eu/health/sites/default/files/preparedness_response/docs/hera_2021_comm_en.pdf
HERA will have dedicated capacities for horizon scanning, foresight, data analysis and
market intelligence, as well as building a continuous exchange with national expertise to build
a common analysis. It will strengthen genome sequencing and environmental monitoring
including wastewater-based surveillance and establish efficient data-sharing mechanisms,
building on the planned European Health Data Space8
and the European Open Science
Cloud9
. The results will feed directly into HERA’s work on research and innovation and the
boosting of EU’s industrial resilience. HERA will swiftly establish operational ties with
global networks to ensure timely and relevant intelligence gathering.
The support programmes that were set as part of HERA Incubator include, for a total budget of €135m, a
whole genome sequencing support framework contract, a national infrastructure support programme and a
capacity building support programme, as well as a support programme and data network related to detection
of SARS-CoV-2 variants in wastewater
Might be of interest to some. Posts from 25 Aug touching on BT progress to market.
Question:
"gjbrandon can you offer any comment on why it was possible for iAbra to call for volunteers for Virolens (Is it DVRG can't or don't need to do same?). On the face of it the task is the same, 150 validated positive and 250 validated negative Covid-19 test results.
"The goal of the evaluation trial is to achieve MHRA approval for the Virolens™ system. This will be achieved by identifying 150 validated positive and 250 validated negative Covid-19 test results. The trial will compare results generated by the Virolens™ device against two different PCR tests processed by independent laboratories. "
"The trial at The Brewery is being conducted by i-Abra and is authorised by the MHRA. It is running from the 3rd February for an initial 7 day period, and is open from 7am-7pm Monday to Friday, and 10am-4pm on Saturday (closed on Sunday)."
https://www.thebrewery.co.uk/blog/virolens-evaluation-trial/
Well that doesn't look so different from:
""The requirement for the UK Target Product Profile ("TPP") Rapid Breath Test requires 150 confirmed positive samples and 250 confirmed negative samples. Additional supervised breath test clinical trials from a larger group is expected to provide sufficient data to meet the desired and acceptable criteria in the TPP to roll out the COVID19 and other pathogen breath tests later this year.""
https://www.londonstockexchange.com/news-article/DVRG/microtox-r-bt-eval-n-of-sars-cov-2-from-breath-test/14902642
Yet in contrast with iAbra from AGM Q&A:
Q21: How can I volunteer to trial the Microtox BT?
Become a COVID 19 patient in ICU
The obvious and acceptable answer would be "because idiot, everything is being sorted and we don't need to seek volunteers to achieve numbers". The less pleasing answer is that there are double standards at play.
With a system that works it would appear to simply be a numbers game for BT. Hence the RNS expectations..
No shortage of Covid so that can't be a problem:
"Scotland has broken the record for the highest number of daily Covid cases since the start of the pandemic for the second time in the course of a week."
https://news.stv.tv/scotland/sharp-rise-in-covid-cases-as-scotland-hits-new-record-high?amp "
Answer:
"@T.Rat the testing protocols are different, requiring different ethical committees with different conditions. That is the most appropriate means of answering in a public forum. @Davidlaw addresses a lot of issues relating to bureaucracy, regardless of how well the technology works, there are so many hurdles from concept last June to market for any medical device. Wastewater will roll out much faster and we have informed the market of an update this quarter"
So a slowness in bringing BT to market not unexpected. But then nor will the contrasting speed of PD installations be a surprise.
Re timings - yes. It's exactly the same technology between PD and BT but of course the BT, being used orally, needs to conform to a whole lot of tests etc. most likely needing the CE mark. PD on the other hand...less restrictions.
I'd also gather both units are being worked on my Microsaic to try and essentially reduce the size of the device. Imagine a miniature breathalyser used by hospitals or police (?!) to detect a number of pathogens. Sounds all very futuristic. When they changed name, they did mention Deep Mind, on the Verge of new technology...
Well done T.
It's not just for my benefit, this kind of activity can create all kinds of really serious problems, what if the idiot decided to go post on multiple BBs that they are all idiots and should be buying DVRG shares asap as it was going to the moon next week...posters would flood this BB with their views......or something more sinister instead. If he can do it to my account he can do it to others, this has to be nipped in the bud now.
Ok, original post reported. Disruptive. Impersonating another account...
Member Info for NewuncIe (the fake ID was created using capital i instead of l), suggest people report this as this is pretty out of order.
Posts (Last 30 Days) 2
Posts (All Time) 2
Last Post 17th Sep 2021
Member Since 16th Sep 2021
t-rat,
my posting history never went away, it's a fake username created today
Looks like LSE Admin are dealing with it now.
NewuncIe, looks like your post history is back.
I can see it's a fake account using capital i instead of the l.....newuncIe obvious to spot which one it is by the posts counter under name shown. What a total ****** and I hope LSE ban you forever.
t.rat,
Looks like some dip**** has decided to clone my username here, no hard to think who that might be.
NewuncIe, only two posts visible when clicking on your name.
I think we might tick higher again, there appears to be a large buyer wanting stock at the moment
newliberty, Gerry also said target of 100 PD for year end remains. Perhaps mugginsthedog too busy being impressed with himself and missed that bit. Business is good...
I didn't post that last one twice, summat up with the lse i think
Bid just improved considerably from 26.5 to 27.3 fwiw
How sad mugginsthedog thinks he has made some great discovery. Yet anybody paying attention is left wondering what they are getting so excited about. Perhaps with that revelation they'll sell?
Broker note 3 August 2021:
"News releases that might be expected to anticipate this include, amongst other things,
widespread regulatory imposition by European governments of real-time virus/pathogen
detection in water/wastewater potentially in tandem with formalisation of DeepVerge’s
far-reaching joint venture with State-owned China Resources, which together present an opportunity to kick-start extended product roll out across multiple jurisdictions in 2H 2021. These, along with STC’s full UK marketing launch prior to expanding into other international territories, suggests Group activity levels are set to step up a gear in the coming months, with the MHRA potentially also awarding Microtox® BT with a CE mark toward the end of Q1 2022. Recognising the scale of the opportunities being presented, TPI has updated its forecasts and financial model for DeepVerge, resulting in a higher price target of 94.7p for the shares (up from 84.8p previously set on 11 January 2021)."
He said it was making slow progress but moving through quicker than many other products in the pharmaceutical system
So we wait a little while longer but will eventually test for an additional 39 other diseases.
The joint development program of work on the PBM-HALE™ breath condensate device from PulmoBioMed is ongoing using multiplex bio-marker binding agents to analyse breath for 40 other diseases which include cancer, neurodegenerative, respiratory and metabolic conditions.
Confirmation of the award:
https://www.modernwater.com/2021/09/17/modern-water-winner-at-2021-china-social-impact-awards/
Courtesy of https://www.linkedin.com/company/modern-water-plc/
GB did effectively a whole presentation on the breathalyser at a previous AGM. I think that we can conclude from that that the breathalyser is an important part of DVRG’s activities. The breathalyser was due to be available commercially Q1 this year. If it has been moved to next year (or beyond) shareholders deserve a proper explanation explaining why , an updated timetable and any risks. To have the delay virtually whispered during a presentation, meaning most people missed it, is totally unacceptable but all too familiar for this company.
Details please.
I've tried explaining it repeatedly, and in different ways. The usual response is "Gerry said just wait a bit longer".
They've made their minds up. GLA.
Hello Newuncle & HSD, If you look at the AVCT news flow, you will see how many live samples were tested for their Covid test, a lot were done in a Spanish hospital and other locations, having said that they failed Porton Down due to their use of frozen samples which did not work well with the test. Having sold here during July I still sit on the sidelines to see if there is an entry point however the interims did not fill me with much confidence, will continue to monitor progress here, GLA. Roly.
Newuncle,
I saw that RNS but unfortunately the sample is too small to draw a conclusive result, especially without additional data to clarify how they arrived at those figures.
That's normal, and it's why small trials are always followed by larger ones. But the real cause for concern is the lack of details. At the very least, the questions I posted at 10:07 should be answered. As I said before, there isn't any good reason not to give investors that information.